S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   202.41 (+3.02%)
FB   168.83 (+1.98%)
MSFT   169.60 (+2.62%)
GOOGL   1,217.01 (+2.86%)
AMZN   2,011.60 (+0.70%)
CGC   14.48 (+0.98%)
NVDA   259.03 (-3.05%)
BABA   199.99 (+1.80%)
MU   46.52 (+0.32%)
TSLA   545.45 (+5.66%)
AMD   49.02 (+3.16%)
T   30.38 (+3.19%)
ACB   0.81 (+1.25%)
F   4.71 (+3.97%)
NFLX   380.15 (+0.05%)
BAC   22.12 (+3.41%)
GILD   74.67 (-3.94%)
DIS   104.95 (+5.39%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   202.41 (+3.02%)
FB   168.83 (+1.98%)
MSFT   169.60 (+2.62%)
GOOGL   1,217.01 (+2.86%)
AMZN   2,011.60 (+0.70%)
CGC   14.48 (+0.98%)
NVDA   259.03 (-3.05%)
BABA   199.99 (+1.80%)
MU   46.52 (+0.32%)
TSLA   545.45 (+5.66%)
AMD   49.02 (+3.16%)
T   30.38 (+3.19%)
ACB   0.81 (+1.25%)
F   4.71 (+3.97%)
NFLX   380.15 (+0.05%)
BAC   22.12 (+3.41%)
GILD   74.67 (-3.94%)
DIS   104.95 (+5.39%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   202.41 (+3.02%)
FB   168.83 (+1.98%)
MSFT   169.60 (+2.62%)
GOOGL   1,217.01 (+2.86%)
AMZN   2,011.60 (+0.70%)
CGC   14.48 (+0.98%)
NVDA   259.03 (-3.05%)
BABA   199.99 (+1.80%)
MU   46.52 (+0.32%)
TSLA   545.45 (+5.66%)
AMD   49.02 (+3.16%)
T   30.38 (+3.19%)
ACB   0.81 (+1.25%)
F   4.71 (+3.97%)
NFLX   380.15 (+0.05%)
BAC   22.12 (+3.41%)
GILD   74.67 (-3.94%)
DIS   104.95 (+5.39%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   202.41 (+3.02%)
FB   168.83 (+1.98%)
MSFT   169.60 (+2.62%)
GOOGL   1,217.01 (+2.86%)
AMZN   2,011.60 (+0.70%)
CGC   14.48 (+0.98%)
NVDA   259.03 (-3.05%)
BABA   199.99 (+1.80%)
MU   46.52 (+0.32%)
TSLA   545.45 (+5.66%)
AMD   49.02 (+3.16%)
T   30.38 (+3.19%)
ACB   0.81 (+1.25%)
F   4.71 (+3.97%)
NFLX   380.15 (+0.05%)
BAC   22.12 (+3.41%)
GILD   74.67 (-3.94%)
DIS   104.95 (+5.39%)
Log in

LON:CLINClinigen Group Share Price, Forecast & News

GBX 525.50
+31.50 (+6.38 %)
(As of 04/7/2020 04:00 PM ET)
Add
Compare
Today's Range
499
Now: GBX 525.50
560.90
50-Day Range
357.80
MA: GBX 634.78
885.50
52-Week Range
350.40
Now: GBX 525.50
1,069
Volume302,753 shs
Average Volume432,646 shs
Market Capitalization£698.12 million
P/E Ratio50.53
Dividend Yield1.36%
BetaN/A
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Segment supplies and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Read More
Clinigen Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.6Community Rank: 3.9Dividend Strength: 2.5Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.61 out of 5 stars


Industry, Sector and Symbol

Industry Drug Delivery
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1283-495010

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£491.70 million
Cash FlowGBX 31.75 per share
Book ValueGBX 332.40 per share

Profitability

Miscellaneous

Employees849
Market Cap£698.12 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CLIN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLIN and its competitors with MarketBeat's FREE daily newsletter.


Clinigen Group (LON:CLIN) Frequently Asked Questions

How has Clinigen Group's stock been impacted by COVID-19 (Coronavirus)?

Clinigen Group's stock was trading at GBX 657 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLIN stock has decreased by 20.0% and is now trading at GBX 525.50. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Clinigen Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Clinigen Group.

How were Clinigen Group's earnings last quarter?

Clinigen Group PLC (LON:CLIN) released its quarterly earnings data on Tuesday, February, 25th. The company reported $30.80 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $31.00 by $0.20. View Clinigen Group's earnings history.

How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group?

Clinigen Group declared a dividend on Tuesday, February 25th. Shareholders of record on Thursday, March 19th will be given a dividend of GBX 2.15 per share on Friday, April 17th. This represents a yield of 0.29%. The ex-dividend date of this dividend is Thursday, March 19th. The official announcement can be accessed at this link. View Clinigen Group's dividend history.

What price target have analysts set for CLIN?

4 equities research analysts have issued 12-month price objectives for Clinigen Group's stock. Their forecasts range from GBX 790 to GBX 1,500. On average, they anticipate Clinigen Group's share price to reach GBX 1,212.50 in the next year. This suggests a possible upside of 130.7% from the stock's current price. View analysts' price targets for Clinigen Group.

Has Clinigen Group been receiving favorable news coverage?

News stories about CLIN stock have been trending very negative this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clinigen Group earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutClinigen Group.

Who are some of Clinigen Group's key competitors?

What other stocks do shareholders of Clinigen Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Application (AAAP), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), Albemarle (ALB), RTI International Metals (RTI), NetApp (NTAP) and StatPro Group (SOG).

Who are Clinigen Group's key executives?

Clinigen Group's management team includes the following people:
  • Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 51)
  • Mr. Nicholas Keher, CFO & Director
  • Ms. Debra Ainge, Chief Operating Officer
  • Matt Parrish, Head of Investor Relations
  • Mr. David Bryant, Director of Corp. Devel.

What is Clinigen Group's stock symbol?

Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."

How do I buy shares of Clinigen Group?

Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Clinigen Group's stock price today?

One share of CLIN stock can currently be purchased for approximately GBX 525.50.

How big of a company is Clinigen Group?

Clinigen Group has a market capitalization of £698.12 million and generates £491.70 million in revenue each year. Clinigen Group employs 849 workers across the globe. View additional information about Clinigen Group.

What is Clinigen Group's official website?

The official website for Clinigen Group is http://www.clinigengroup.com/.

How can I contact Clinigen Group?

Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010.

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel